Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura have?
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura has 50 citations in the OpenAlex counts ScholarIQ stores.
When was Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura published?
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura has 2023 year in the ScholarIQ index.
What is the open-access status of Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura?
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura has bronze oa status in the ScholarIQ index.
What is the DOI of Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura?
The DOI for Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura is on the source record.
What is the PMID of Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura?
The PMID for Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura is on the source record.
What is the OpenAlex record for Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura?
The OpenAlex for Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura is on the source record.